m5 114 Search Results


94
ATCC hybridoma supernatant
Hybridoma Supernatant, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hybridoma supernatant/product/ATCC
Average 94 stars, based on 1 article reviews
hybridoma supernatant - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Bio X Cell anti mouse mhcii
Neutralization of IL-10R signaling reduces the lymphoma burden in a syngeneic transplantation model and reduces the intratumoral frequencies of regulatory T-cells. a-e , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells isolated from the spleens of Eµ-Myc-transgenic donors, and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights and the frequencies and surface marker expression of various lymph node leukocyte populations by flow cytometry. An initial dose of 500 µg anti-IL-10RA neutralizing or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. (a) Combined axillary and inguinal lymph node weights of anti-IL-10RA- or control IgG antibody-treated mice. (b) Tumor B-cell frequencies in axillary and inguinal lymph node preparations as determined by staining for CD19 and CD45, of the mice shown in A, alongside representative FACS plots of one mouse per group. The Ki67 signal of the tumor B-cells is shown as well. See suppl. Figure 5a for the complete gating strategy. (c,d) Frequencies of TCRβ + T-cells, of CD4 + T-cells and of CD8 + T-cells among all leukocytes, as determined by flow cytometry. See suppl. Figure 5c for the gating strategy. (e) Frequencies of FoxP3 + Tregs among all CD4 + T-cells, as determined by intracellular staining for FoxP3; representative FACS plots of one mouse per group are shown alongside the summary plot for all mice. f,g , Frequencies of tumor B-cells and of CD4 + T-cells in axillary and inguinal lymph node preparations as determined by staining for CD19, CD4 and CD45, of anti-IL-10R- or control IgG antibody-treated WT and Foxp3 -iDTR mice. Mice received twice weekly i.p. doses of 20 ng/g diphtheria toxin (DT) to deplete Tregs, starting from one day before tumor cell injection. Treg depletion efficiency was >90%. Four mice were each injected i.v. with 100ʹ000 Tregs that had been sorted from the tumors of Foxp3 -iDTR mice based on their GFP expression, on day four post tumor cell transplantation. h , <t>MHCII</t> expression as determined by flow cytometry, of a subset of the mice shown in a-e. A representative histogram of the MHCII signal of two representative mice is shown alongside the summary plot of all mice. i-k , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights (i), tumor B-cell frequencies (j) and CD4 + /CD8 + T-cell frequencies (k). An initial dose of 500 µg anti-IL-10RA neutralizing and/or MHCII-blocking or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. Data in a-e are pooled from four independent experiments; data in f,g are pooled from one to six experiments, Treg transfer was only performed once. Data in hare from three experiments and data in i-k are from two experiments; note that several mice were lost to follow-up by flow cytometry. Horizontal lines indicate medians. Statistical comparisons were performed either by one-way ANOVA (in the case of normal data distribution) or by non-parametric ANOVA (Kruskal–Wallis test, in the case of non-normal data distribution) with Tukey’s multiple comparisons correction. ns, not significant, *p < .05, **p < .01 ***p < .005, ****p < .001
Anti Mouse Mhcii, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse mhcii/product/Bio X Cell
Average 94 stars, based on 1 article reviews
anti mouse mhcii - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Novus Biologicals nbp1
Neutralization of IL-10R signaling reduces the lymphoma burden in a syngeneic transplantation model and reduces the intratumoral frequencies of regulatory T-cells. a-e , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells isolated from the spleens of Eµ-Myc-transgenic donors, and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights and the frequencies and surface marker expression of various lymph node leukocyte populations by flow cytometry. An initial dose of 500 µg anti-IL-10RA neutralizing or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. (a) Combined axillary and inguinal lymph node weights of anti-IL-10RA- or control IgG antibody-treated mice. (b) Tumor B-cell frequencies in axillary and inguinal lymph node preparations as determined by staining for CD19 and CD45, of the mice shown in A, alongside representative FACS plots of one mouse per group. The Ki67 signal of the tumor B-cells is shown as well. See suppl. Figure 5a for the complete gating strategy. (c,d) Frequencies of TCRβ + T-cells, of CD4 + T-cells and of CD8 + T-cells among all leukocytes, as determined by flow cytometry. See suppl. Figure 5c for the gating strategy. (e) Frequencies of FoxP3 + Tregs among all CD4 + T-cells, as determined by intracellular staining for FoxP3; representative FACS plots of one mouse per group are shown alongside the summary plot for all mice. f,g , Frequencies of tumor B-cells and of CD4 + T-cells in axillary and inguinal lymph node preparations as determined by staining for CD19, CD4 and CD45, of anti-IL-10R- or control IgG antibody-treated WT and Foxp3 -iDTR mice. Mice received twice weekly i.p. doses of 20 ng/g diphtheria toxin (DT) to deplete Tregs, starting from one day before tumor cell injection. Treg depletion efficiency was >90%. Four mice were each injected i.v. with 100ʹ000 Tregs that had been sorted from the tumors of Foxp3 -iDTR mice based on their GFP expression, on day four post tumor cell transplantation. h , <t>MHCII</t> expression as determined by flow cytometry, of a subset of the mice shown in a-e. A representative histogram of the MHCII signal of two representative mice is shown alongside the summary plot of all mice. i-k , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights (i), tumor B-cell frequencies (j) and CD4 + /CD8 + T-cell frequencies (k). An initial dose of 500 µg anti-IL-10RA neutralizing and/or MHCII-blocking or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. Data in a-e are pooled from four independent experiments; data in f,g are pooled from one to six experiments, Treg transfer was only performed once. Data in hare from three experiments and data in i-k are from two experiments; note that several mice were lost to follow-up by flow cytometry. Horizontal lines indicate medians. Statistical comparisons were performed either by one-way ANOVA (in the case of normal data distribution) or by non-parametric ANOVA (Kruskal–Wallis test, in the case of non-normal data distribution) with Tukey’s multiple comparisons correction. ns, not significant, *p < .05, **p < .01 ***p < .005, ****p < .001
Nbp1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nbp1/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
nbp1 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
novus biologicals nbp2-21789
Primary antibodies used
Nbp2 21789, supplied by novus biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nbp2-21789/product/novus biologicals
Average 94 stars, based on 1 article reviews
nbp2-21789 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Novus Biologicals ra mab igg 2b
Antibodies
Ra Mab Igg 2b, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ra mab igg 2b/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
ra mab igg 2b - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Novus Biologicals rat anti mhc ii
Antibodies
Rat Anti Mhc Ii, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat anti mhc ii/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
rat anti mhc ii - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

92
Novus Biologicals alexa fluor 647 anti mouse mhc ii
Antibodies
Alexa Fluor 647 Anti Mouse Mhc Ii, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alexa fluor 647 anti mouse mhc ii/product/Novus Biologicals
Average 92 stars, based on 1 article reviews
alexa fluor 647 anti mouse mhc ii - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

93
fluidigm anti mouse i a i e m5 114 15 2 174yb
Antibodies
Anti Mouse I A I E M5 114 15 2 174yb, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse i a i e m5 114 15 2 174yb/product/fluidigm
Average 93 stars, based on 1 article reviews
anti mouse i a i e m5 114 15 2 174yb - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
fluidigm anti mouse i a i e m5 114 15 2 209bi
Antibodies
Anti Mouse I A I E M5 114 15 2 209bi, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse i a i e m5 114 15 2 209bi/product/fluidigm
Average 93 stars, based on 1 article reviews
anti mouse i a i e m5 114 15 2 209bi - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Becton Dickinson anti-ia (m5/114
Antibodies
Anti Ia (M5/114, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-ia (m5/114/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-ia (m5/114 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Insight Biotechnology Ltd ia/ie allophycocyanin #m5/114.15.2 antibody
Antibodies
Ia/Ie Allophycocyanin #M5/114.15.2 Antibody, supplied by Insight Biotechnology Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ia/ie allophycocyanin #m5/114.15.2 antibody/product/Insight Biotechnology Ltd
Average 90 stars, based on 1 article reviews
ia/ie allophycocyanin #m5/114.15.2 antibody - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Neutralization of IL-10R signaling reduces the lymphoma burden in a syngeneic transplantation model and reduces the intratumoral frequencies of regulatory T-cells. a-e , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells isolated from the spleens of Eµ-Myc-transgenic donors, and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights and the frequencies and surface marker expression of various lymph node leukocyte populations by flow cytometry. An initial dose of 500 µg anti-IL-10RA neutralizing or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. (a) Combined axillary and inguinal lymph node weights of anti-IL-10RA- or control IgG antibody-treated mice. (b) Tumor B-cell frequencies in axillary and inguinal lymph node preparations as determined by staining for CD19 and CD45, of the mice shown in A, alongside representative FACS plots of one mouse per group. The Ki67 signal of the tumor B-cells is shown as well. See suppl. Figure 5a for the complete gating strategy. (c,d) Frequencies of TCRβ + T-cells, of CD4 + T-cells and of CD8 + T-cells among all leukocytes, as determined by flow cytometry. See suppl. Figure 5c for the gating strategy. (e) Frequencies of FoxP3 + Tregs among all CD4 + T-cells, as determined by intracellular staining for FoxP3; representative FACS plots of one mouse per group are shown alongside the summary plot for all mice. f,g , Frequencies of tumor B-cells and of CD4 + T-cells in axillary and inguinal lymph node preparations as determined by staining for CD19, CD4 and CD45, of anti-IL-10R- or control IgG antibody-treated WT and Foxp3 -iDTR mice. Mice received twice weekly i.p. doses of 20 ng/g diphtheria toxin (DT) to deplete Tregs, starting from one day before tumor cell injection. Treg depletion efficiency was >90%. Four mice were each injected i.v. with 100ʹ000 Tregs that had been sorted from the tumors of Foxp3 -iDTR mice based on their GFP expression, on day four post tumor cell transplantation. h , MHCII expression as determined by flow cytometry, of a subset of the mice shown in a-e. A representative histogram of the MHCII signal of two representative mice is shown alongside the summary plot of all mice. i-k , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights (i), tumor B-cell frequencies (j) and CD4 + /CD8 + T-cell frequencies (k). An initial dose of 500 µg anti-IL-10RA neutralizing and/or MHCII-blocking or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. Data in a-e are pooled from four independent experiments; data in f,g are pooled from one to six experiments, Treg transfer was only performed once. Data in hare from three experiments and data in i-k are from two experiments; note that several mice were lost to follow-up by flow cytometry. Horizontal lines indicate medians. Statistical comparisons were performed either by one-way ANOVA (in the case of normal data distribution) or by non-parametric ANOVA (Kruskal–Wallis test, in the case of non-normal data distribution) with Tukey’s multiple comparisons correction. ns, not significant, *p < .05, **p < .01 ***p < .005, ****p < .001

Journal: Oncoimmunology

Article Title: Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma

doi: 10.1080/2162402X.2021.2003533

Figure Lengend Snippet: Neutralization of IL-10R signaling reduces the lymphoma burden in a syngeneic transplantation model and reduces the intratumoral frequencies of regulatory T-cells. a-e , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells isolated from the spleens of Eµ-Myc-transgenic donors, and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights and the frequencies and surface marker expression of various lymph node leukocyte populations by flow cytometry. An initial dose of 500 µg anti-IL-10RA neutralizing or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. (a) Combined axillary and inguinal lymph node weights of anti-IL-10RA- or control IgG antibody-treated mice. (b) Tumor B-cell frequencies in axillary and inguinal lymph node preparations as determined by staining for CD19 and CD45, of the mice shown in A, alongside representative FACS plots of one mouse per group. The Ki67 signal of the tumor B-cells is shown as well. See suppl. Figure 5a for the complete gating strategy. (c,d) Frequencies of TCRβ + T-cells, of CD4 + T-cells and of CD8 + T-cells among all leukocytes, as determined by flow cytometry. See suppl. Figure 5c for the gating strategy. (e) Frequencies of FoxP3 + Tregs among all CD4 + T-cells, as determined by intracellular staining for FoxP3; representative FACS plots of one mouse per group are shown alongside the summary plot for all mice. f,g , Frequencies of tumor B-cells and of CD4 + T-cells in axillary and inguinal lymph node preparations as determined by staining for CD19, CD4 and CD45, of anti-IL-10R- or control IgG antibody-treated WT and Foxp3 -iDTR mice. Mice received twice weekly i.p. doses of 20 ng/g diphtheria toxin (DT) to deplete Tregs, starting from one day before tumor cell injection. Treg depletion efficiency was >90%. Four mice were each injected i.v. with 100ʹ000 Tregs that had been sorted from the tumors of Foxp3 -iDTR mice based on their GFP expression, on day four post tumor cell transplantation. h , MHCII expression as determined by flow cytometry, of a subset of the mice shown in a-e. A representative histogram of the MHCII signal of two representative mice is shown alongside the summary plot of all mice. i-k , C57BL/6 mice were intravenously injected with 1 Mio >90% pure lymphoma cells and examined at the study endpoint (10–15 days post injection) with respect to their lymph node weights (i), tumor B-cell frequencies (j) and CD4 + /CD8 + T-cell frequencies (k). An initial dose of 500 µg anti-IL-10RA neutralizing and/or MHCII-blocking or control IgG antibody was i.p. injected shortly before tumor cell inoculation, followed by twice weekly injections of 300 µg antibody. Control mice did not receive tumor cells. Data in a-e are pooled from four independent experiments; data in f,g are pooled from one to six experiments, Treg transfer was only performed once. Data in hare from three experiments and data in i-k are from two experiments; note that several mice were lost to follow-up by flow cytometry. Horizontal lines indicate medians. Statistical comparisons were performed either by one-way ANOVA (in the case of normal data distribution) or by non-parametric ANOVA (Kruskal–Wallis test, in the case of non-normal data distribution) with Tukey’s multiple comparisons correction. ns, not significant, *p < .05, **p < .01 ***p < .005, ****p < .001

Article Snippet: Anti-mouse IL-10RA (1B1.3A), anti-mouse MHCII (M5/114), anti-mouse PD-L1 (10 F.9G2), and isotype control antibodies were purchased from BioXCell.

Techniques: Neutralization, Transplantation Assay, Injection, Isolation, Transgenic Assay, Marker, Expressing, Flow Cytometry, Control, Staining, Blocking Assay

Primary antibodies used

Journal: American Journal of Physiology - Gastrointestinal and Liver Physiology

Article Title: The antioxidant glutathione protects against enteric neuron death in situ, but its depletion is protective during colitis

doi: 10.1152/ajpgi.00165.2017

Figure Lengend Snippet: Primary antibodies used

Article Snippet: Rat anti-MHC II , 1:200 , Novus Biologicals, Littleton, CO , NBP2-21789.

Techniques:

Antibodies

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: Azetidine-2-Carboxylic Acid-Induced Oligodendrogliopathy: Relevance to the Pathogenesis of Multiple Sclerosis

doi: 10.1093/jnen/nlac028

Figure Lengend Snippet: Antibodies

Article Snippet: MHC Class II (M5/114.15.2) , NBP1-43312 , Ra mAb IgG 2b , 1:100 , Novus Biologicals.

Techniques: Concentration Assay